At the time of writing, Zymeworks BC Inc [ZYME] stock is trading at $19.38, up 0.41%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZYME shares have gain 9.68% over the last week, with a monthly amount glided 13.47%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on October 14, 2025, and kept the price target unchanged to $26. On October 10, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $30 on the stock. TD Cowen started tracking the stock assigning a Buy rating. JP Morgan upgraded its rating to a Overweight but $18 remained the price target by the analyst firm on December 16, 2024. Leerink Partners upgraded its rating to Outperform for this stock on November 07, 2024, and upped its price target to $25. In a note dated November 01, 2024, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $12.
For the past year, the stock price of Zymeworks BC Inc fluctuated between $9.03 and $19.50. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $19.38 at the most recent close of the market. An investor can expect a potential return of 34.16% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
According to Zymeworks BC Inc [NASDAQ:ZYME], the company’s sales were 122.87M for trailing twelve months, which represents an 153.21% jump. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.67%, Pretax Profit Margin comes in at -0.55%, and Net Profit Margin reading is -0.6%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.22 and Total Capital is -0.22. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 19.12 points at the first support level, and at 18.85 for the second support level. However, for the 1st resistance point, the stock is sitting at 19.53, and for the 2nd resistance point, it is at 19.67.
Ratios To Look Out For
It is important to note that Zymeworks BC Inc [NASDAQ:ZYME] has a current ratio of 7.69. As well, the Quick Ratio is 7.69, while the Cash Ratio is 2.55. Considering the valuation of this stock, the price to sales ratio is 11.95, the price to book ratio is 4.37.
Transactions by insiders
Recent insider trading involved EcoR1 Capital, LLC, Director, that happened on May 15 ’25 when 49502.0 shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 19 ’25 to buy 5919.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 73953.0 shares on Apr 16 ’25.
